Cannabis News Today – July 23, 2024
Welcome to “Cannabis News Today,” a summary of the cannabis industry’s stock and regulatory updates.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD) has doubled the flower capacity of its Maryland cultivation facility, preparing for retail and wholesale distribution by Q4 2024. The facility expansion includes nine new grow rooms and aims to meet increasing demand for MariMed’s flower, concentrates, and edibles. Read the full article on the TDR Website!
Kamala Harris’s emergence as the Democratic frontrunner has caused cannabis stocks to rise due to potential policy changes. However, political uncertainty and skepticism remain regarding the impact of her potential reforms. Read the full article on the TDR Website!
Next week, major North American cannabis companies will start releasing their Q2 2024 earnings, with Tilray reporting its full-year Q4 2024 earnings. Earnings are announced via press releases before or after market hours, followed by analyst conference calls within 24 hours, with TDR providing livestream discussions and editorials. Read the full article on the TDR Website!
Tilray’s Aphria RX facility in Germany received the first cannabis cultivation license under MedCanG, increasing production capacity nearly fivefold from three to 31 strains. This expansion boosts patient access to high-quality medical cannabis. Read the full article on the TDR Website!
A new study suggests lesser-known cannabis compounds may have potential as anti-cancer agents, particularly against multiple myeloma. The findings highlight the therapeutic promise of these components, which could lead to new treatment approaches.
The Minority Cannabis Business Association informed the DEA that rescheduling marijuana could create over 50,000 new jobs. This statement was made on the final day of the public comment period on marijuana rescheduling.
Senator Mike Braun criticized the lack of transparency in the marijuana rescheduling process, expressing concerns about how decisions are made. His comments reflect ongoing debates about the federal handling of marijuana policy.
A lawsuit by investors against Canopy Growth Corporation (TSX: WEED, Nasdaq: CGC) was dismissed, ending allegations that the company misled them about its financial health. The court’s decision removes a legal challenge facing the cannabis company.
Read more cannabis news on the TDR Website!
